p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up.
作者信息
Stopsack Konrad H, Salles Daniela Correia, Vaselkiv J Bailey, Grob Sydney T, Mucci Lorelei A, Lotan Tamara L
机构信息
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
出版信息
Eur Urol Oncol. 2023 Feb;6(1):110-112. doi: 10.1016/j.euo.2021.12.003. Epub 2021 Dec 27.
Abstract
摘要
相似文献
1
p53 Immunohistochemistry to Identify Very High-risk Primary Prostate Cancer: A Prospective Cohort Study with Three Decades of Follow-up.p53免疫组化用于识别极高风险原发性前列腺癌：一项长达三十年随访的前瞻性队列研究
Eur Urol Oncol. 2023 Feb;6(1):110-112. doi: 10.1016/j.euo.2021.12.003. Epub 2021 Dec 27.
2
Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.前列腺癌和前列腺上皮内瘤变中p53蛋白的免疫组织化学测定
Urol Int. 1997;58(4):199-202. doi: 10.1159/000282983.
3
An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer.评估p53和Ki-67标志物在前列腺癌中的预测价值。
J Surg Oncol. 1998 Jan;67(1):33-7. doi: 10.1002/(sici)1096-9098(199801)67:1<33::aid-jso7>3.0.co;2-n.
4
5
p53 protein and gene alterations in pathological stage C prostate carcinoma.病理C期前列腺癌中p53蛋白与基因改变
J Urol. 1997 Aug;158(2):510-4.
6
Clinical significance of p53 alterations in surgically treated prostate cancers.手术治疗前列腺癌中p53改变的临床意义
Mod Pathol. 2008 Nov;21(11):1371-8. doi: 10.1038/modpathol.2008.104. Epub 2008 Jun 13.
7
p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?前列腺癌区域淋巴结转移中p53的改变：进展的标志物？
Cancer. 1999 Jun 1;85(11):2455-9.
8
Combined Loss of EAF2 and p53 Induces Prostate Carcinogenesis in Male Mice.EAF2和p53的联合缺失诱导雄性小鼠前列腺癌发生。
Endocrinology. 2017 Dec 1;158(12):4189-4205. doi: 10.1210/en.2017-00409.
9
P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.P53肿瘤抑制基因突变主要定位于人类原发性和转移性前列腺癌的第7外显子。
Br J Cancer. 1996 Jul;74(2):264-8. doi: 10.1038/bjc.1996.349.
10
p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.p53免疫染色引导的激光捕获显微切割（p53-LCM）可确定原发性前列腺癌中p53蛋白呈阳性的局灶区域是否存在p53基因突变。
Prostate Cancer Prostatic Dis. 2003;6(4):281-5. doi: 10.1038/sj.pcan.4500665.
引用本文的文献
1
Investigating Intensity and Percentage of p53 Nuclear Expression in Prostate Cancer: Findings from a Cohort of U.S. Military Veterans.研究前列腺癌中p53核表达的强度和百分比：来自美国退伍军人队列的研究结果。
Cancers (Basel). 2025 Mar 17;17(6):1004. doi: 10.3390/cancers17061004.
2
promotes oncogenesis and lethal progression of prostate cancer.促进前列腺癌的致癌作用和致死性进展。
Proc Natl Acad Sci U S A. 2024 Sep 3;121(36):e2405543121. doi: 10.1073/pnas.2405543121. Epub 2024 Aug 27.
3
Associations between Etiologic or Prognostic Tumor Tissue Markers and Neighborhood Contextual Factors in Male Health Professionals Diagnosed with Prostate Cancer.男性健康专业人员前列腺癌发病的病因或预后肿瘤组织标志物与邻里环境因素之间的关联。
Cancer Epidemiol Biomarkers Prev. 2023 Aug 1;32(8):1120-1123. doi: 10.1158/1055-9965.EPI-23-0217.
4
Clonal relationships of adjacent Gleason pattern 3 and Gleason pattern 5 lesions in Gleason Scores 3+5=8 and 5+3=8.在 Gleason 评分 3+5=8 和 5+3=8 中，相邻的 Gleason 模式 3 和 Gleason 模式 5 病变的克隆关系。
Hum Pathol. 2022 Dec;130:18-24. doi: 10.1016/j.humpath.2022.10.010. Epub 2022 Oct 26.
Zotero 插件